Program Outline:  International Conference on Drug-Drug Interactions (DDI-2008)

 

 

Pre-conference Workshop (June 2, 2008):

 

Current Practice:  Time-dependent inhibition (TDI) of drug metabolism in drug development

 

  • Overview: TDI and drug development.  Magang Shou, Amgen Inc.; Thousand Oaks, CA

 

  • cDNA and liver microsome TDI assays.  Chuang Lu, Millennium Pharmaceuticals, Inc.; Cambridge, MA

 

  • Human hepatocyte TDI assays.  Dermot McGinnity, AstraZeneca.

 

  • Cytotoxicity of time-dependent P450 inhibitors in human hepatocytes.  Albert P. Li, APSciences and IVAL; Columbia, MD

 

 

Main Conference (June 3-4): 

 

June 3, 2008

 

Session I:  General Overview of DDI Status

           

  • NMEs approved in 2007-8. Carol Collins, University of Washington; Seattle, WA

 

  • Literature review 2007-8:  Clinical studies.  Houda Hachad ,University of Washington; Seattle, WA

 

Session II:  Enzyme Inhibition and Induction

 

  • Significance of Time-Dependent P450 Inhibition in drug-drug interactions and drug toxicity.  Larry Wienkers, Amgen Inc.; Seattle, WA

 

  • Time-dependent and non-time dependent P450 inhibition assays with intact human hepatocytes.  Dermot McGinnity, AstraZeneca.

 

  • Difficulties with the interpretation of CYP3A4 time-dependent inhibition data. Michael Schrag, Array Biopharmaceuticals; Boulder, CO

 

  • Prediction of clinical DDI outcome with in vitro human hepatocyte enzyme induction results.   Magang Shou, Amgen Inc.; Thousand Oaks, CA

 

  • Consideration of plasma and intrahepatic free and bound drug concentrations in IVIVC. Chuang Lu, Millennium Pharmaceuticals, Inc.; Cambridge, MA

                       

 

June 4, 2008

 

Session III:  Transporters: 

 

  • Kinetic evaluation of compounds as substrates or inhibitors for transporters with cell based assays and its application.  Steven Louie, PKDM, Amgen.

 

  • Transport-Metabolism Cross Talk. Maciej J. Zamek-Gliszczynski, Lilly Research Labs; Indianapolis, IN

 

  • Pharmacogenetics of transporters.  Reinhold Kerb, AstraZeneca; Stuttgart, Germany

 

  • Non-Pgp Transporter Assays: Relevance to prediction of Drug Interactions.  Alexander Treiber, Actelion.

 

Session IV:  DDI of Biologicals

 

  • Mechanism of DDI with biologic drugs.  Danny Shen, University of Washington; Seattle, WA (Invited)

 

  • Pharmacokinetic Drug-Drug Interactions for Therapeutic Monoclonal Antibodies - Clinical Relevance and Future Perspectives.  Honghui Zhou, Johnson & Johnson Biotechnology, Immunology & Oncology; Malvern, PA